Veracyte Acquires C2i Genomics for $70M, Expanding into Minimal Residual Disease Detection
What You Should Know:
– Veracyte, Inc. (Nasdaq: VCYT), a cancer diagnostics company acquires C2i Genomics, Inc., a pioneer in minimal residual disease (MRD) detection.
– Under the terms of the agreement, Veracyte will pay $70…
Continue Reading